Table 1 Baseline characteristics of patients

Patient number

635

188

Age, year

 Mean ± standard deviation (SD)

61.87 ± 14.33

70.53 ± 12.75

 < 0.001

Sex

 Male/female

309/326

99/89

0.38

Treatment experience

 Naïve/experienced

605/30

181/7

0.7

HBV coinfection

 Absent/present

565/70

173/15

0.29

Prior HCC history

 No/yes

627/8

154/34

 < 0.001

Ribavirin usage

 No/yes

631/4

162/26

 < 0.001

Child–Pugh–Turcotte class

 A/B/C

632/3/0

164/23/1

 < 0.001

Diabetes mellitus

 No/Yes

509/126

143/45

0.27

HCV RNA, IU/mL

 < 800,000/ ≥ 800,000

195/440

80/108

 < 0.05

HCV RNA, IU/mL, median (range)

2,261,880 (17–39,902,035)

1,047,236 (51–31,094,685)

 < 0.001

Hemoglobin, g/dL, mean ± SD

13.67 ± 1.8

12.82 ± 2.08

 < 0.001

White blood cell count, 10⁹cells/L, mean ± SD

6.77 ± 2.06

5.8 ± 6.69

0.05

Platelet count, 10⁹cells/L, mean ± SD

218.80 ± 66.93

129.14 ± 51.23

 < 0.001

Albumin, g/dL, mean ± SD

4.29 ± 0.35

3.85 ± 0.51

 < 0.001

Total bilirubin, mg/dL, mean ± SD

0.84 ± 0.64

1.27 ± 1.01

 < 0.001

AST, U/L, mean ± SD

38.83 ± 24.84

95.62 ± 68.27

 < 0.001

ALT, U/L, mean ± SD

51.69 ± 56.24

97.24 ± 88.12

 < 0.001

Creatinine, mg/dL, mean ± SD

1.00 ± 1.04

0.96 ± 0.54

0.53

eGFR, mL/min/1.73m², mean ± SD

85.77 ± 26.23

82.55 ± 28.28

0.15

Alpha-fetoprotein, ng/mL, median (range)

3 (0.7–114.1)

5.7 (1.2–52,225.3)

 < 0.001

1a

19

8

27 (3.28%)

1b

267

59

326 (39.61%)

2

301

103

404 (49.09%)

3

2

2

4 (0.49%)

6

14

4

18 (2.19%)

Mixed

30

11

41 (4.98%)

No data

2

1

3 (0.36%)